An Orange Juice Study Found No Heart Benefit. Its Press Release Suggested One.

What the trial actually tested

Researchers ran a randomized, double blind, three period crossover trial in 37 men with high waist circumference. Each man spent six weeks on each of three drinks: 330 milliliters a day of 100 percent orange juice, a control drink matched for sugar and calories, and that same control drink with 210 milligrams a day of added hesperidin, the main flavanone in oranges. Because it was a crossover, every man acted as his own comparison.

The results, published in Food and Function, were straightforward. Blood levels of the citrus flavanones went up, so the compounds were genuinely absorbed. Gene expression shifted, with some genes linked to blood vessel pathways moving up and others moving down. But blood pressure and blood vessel function did not measurably improve on either the juice or the hesperidin drink. The paper's own title says it plainly: orange juice and hesperidin increased flavanone exposure without any detectable short term vascular benefit.

What the press release said

On September 16, 2026, the Fruit Juice Science Centre, a body funded by the juice industry, distributed the study under the headline "Could a daily glass of orange juice support heart health?"

Here is the part that makes this worth writing about. Inside that same release, the lead researcher, Christine Morand of INRAE and Université Clermont Auvergne, is quoted accurately. She says the molecular changes did not lead to measurable short term improvements in blood pressure or blood vessel health in this group. A few paragraphs later, a registered dietitian is quoted saying "a small daily glass could be a simple way to benefit cardiovascular health via multiple pathways."

Both statements sit in one document. The researcher's matches the paper. The heart benefit framing does not come from this trial. One detail matters for fairness: the funder of the press release is an industry body, which is a separate question from who funded the trial itself, and I have not seen the paper's own funding statement.

Both statements sit in one document.

Why this matters for hesperidin supplements

Hesperidin and citrus bioflavonoids show up across circulation, vein and heart health formulas, usually sold on a vascular benefit. There is earlier research pointing that way, including a 2011 crossover trial in the American Journal of Clinical Nutrition that reported positive vascular effects, and that literature deserves to be weighed rather than ignored. But a well controlled trial at a realistic dose, testing the exact endpoint the ingredient is marketed on and finding no measurable change, is a meaningful mark against the claim.

How to spot this yourself

Three questions caught this one, and they work on almost any supplement headline. Who issued the press release, the university or an industry body? Does the researcher's own quote match the headline? And did the study measure an outcome you care about, like blood pressure, or only a marker, like gene expression, that might someday lead to one?